Literature DB >> 37813

Neurotransmitter receptors in frontal cortex of schizophrenics.

J P Bennett, S J Enna, D B Bylund, J C Gillin, R J Wyatt, S H Snyder.   

Abstract

Frontal cerebral cortex brain samples from schizophrenics and controls have been assayed for binding associated with muscarinic cholinergic, serotonin (5HT), gamma-aminobutyric acid (GABA), and beta-adrenergic receptors as well as for the activity of the GABA-synthesizing enzyme glutamic acid decarboxylase (GAD). Binding levels of tritium-LSD, presumably associated with postsynaptic 5HT receptors, were reduced 40% to 50% in samples from schizophrenics in three independent studies, whereas no other consistent alteration was observed in levels of binding associated with other receptors or in the activity of GAD. This change in receptor binding levels does not seem to be attributable to postmortem changes, to influence of drugs received by the patients, or to demographic features of the patient populations.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 37813     DOI: 10.1001/archpsyc.1979.01780090013001

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  19 in total

1.  Effects of phencyclidine (PCP) and MK 801 on the EEGq in the prefrontal cortex of conscious rats; antagonism by clozapine, and antagonists of AMPA-, alpha(1)- and 5-HT(2A)-receptors.

Authors:  Claude Sebban; Brigitte Tesolin-Decros; Jorge Ciprian-Ollivier; Laurent Perret; Michael Spedding
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature.

Authors:  Salma R I Ribeiz; Débora P Bassitt; Jony A Arrais; Renata Avila; David C Steffens; Cássio M C Bottino
Journal:  CNS Drugs       Date:  2010-04       Impact factor: 5.749

3.  Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients.

Authors:  R C Arora; H Y Meltzer
Journal:  J Neural Transm Gen Sect       Date:  1991

Review 4.  Serotonin, dopamine and their interactions in schizophrenia.

Authors:  R S Kahn; M Davidson
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Neuropathological changes in the nucleus basalis in schizophrenia.

Authors:  M R Williams; R Marsh; C D Macdonald; J Jain; R K B Pearce; S R Hirsch; O Ansorge; S M Gentleman; M Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-12-11       Impact factor: 5.270

6.  Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine.

Authors:  L Naylor; B Dean; K Opeskin; G Pavey; C Hill; N Keks; D Copolov
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

7.  The binding of [3H]-5-hydroxytryptamine to homogenates of human brain.

Authors:  E Dehlin; J Marcusson; C J Fowler; B Winblad
Journal:  J Neural Transm       Date:  1982       Impact factor: 3.575

Review 8.  Differential changes in serotonin 5-HT1A and 5-HT2 receptor binding in patients with chronic schizophrenia.

Authors:  T Hashimoto; N Kitamura; Y Kajimoto; Y Shirai; O Shirakawa; T Mita; N Nishino; C Tanaka
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 9.  The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine.

Authors:  J N Joyce
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 10.  The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system.

Authors:  D C Ohuoha; T M Hyde; J E Kleinman
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.